These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18711013)

  • 1. Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines.
    Shapiro BP; Owan TE; Mohammed SF; Meyer DM; Mills LD; Schalkwijk CG; Redfield MM
    Circulation; 2008 Sep; 118(10):1002-10. PubMed ID: 18711013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart.
    Liu J; Masurekar MR; Vatner DE; Jyothirmayi GN; Regan TJ; Vatner SF; Meggs LG; Malhotra A
    Am J Physiol Heart Circ Physiol; 2003 Dec; 285(6):H2587-91. PubMed ID: 12946933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid signaling in transition to heart failure with normal ejection fraction.
    Shapiro BP; Owan TE; Mohammed S; Kruger M; Linke WA; Burnett JC; Redfield MM
    Hypertension; 2008 Feb; 51(2):289-95. PubMed ID: 18086943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.
    Vaitkevicius PV; Lane M; Spurgeon H; Ingram DK; Roth GS; Egan JJ; Vasan S; Wagle DR; Ulrich P; Brines M; Wuerth JP; Cerami A; Lakatta EG
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1171-5. PubMed ID: 11158613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium.
    LeWinter MM; Taatjes D; Ashikaga T; Palmer B; Bishop N; VanBuren P; Bell S; Donaldson C; Meyer M; Margulies KB; Redfield M; Bull DA; Zile M
    Physiol Rep; 2017 Nov; 5(20):. PubMed ID: 29066596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crosslink breakers: a new approach to cardiovascular therapy.
    Susic D; Varagic J; Ahn J; Frohlich ED
    Curr Opin Cardiol; 2004 Jul; 19(4):336-40. PubMed ID: 15218393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letter by Hartog et al. regarding article, "Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines".
    Hartog JW; Willemsen S; Voors AA
    Circulation; 2009 Mar; 119(10):e233; author reply e234. PubMed ID: 19289645
    [No Abstract]   [Full Text] [Related]  

  • 8. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness.
    Steppan J; Tran H; Benjo AM; Pellakuru L; Barodka V; Ryoo S; Nyhan SM; Lussman C; Gupta G; White AR; Daher JP; Shoukas AA; Levine BD; Berkowitz DE
    Exp Gerontol; 2012 Aug; 47(8):565-72. PubMed ID: 22569357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats.
    Susic D; Varagic J; Ahn J; Frohlich ED
    Am J Hypertens; 2004 Apr; 17(4):328-33. PubMed ID: 15062886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakers of advanced glycation end products restore large artery properties in experimental diabetes.
    Wolffenbuttel BH; Boulanger CM; Crijns FR; Huijberts MS; Poitevin P; Swennen GN; Vasan S; Egan JJ; Ulrich P; Cerami A; Lévy BI
    Proc Natl Acad Sci U S A; 1998 Apr; 95(8):4630-4. PubMed ID: 9539789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.
    Satheesan S; Figarola JL; Dabbs T; Rahbar S; Ermel R
    Br J Pharmacol; 2014 Jun; 171(12):3103-14. PubMed ID: 24611770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vasa vasorum flow on structure and function of the aorta in experimental animals.
    Stefanadis C; Vlachopoulos C; Karayannacos P; Boudoulas H; Stratos C; Filippides T; Agapitos M; Toutouzas P
    Circulation; 1995 May; 91(10):2669-78. PubMed ID: 7743631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.
    Candido R; Forbes JM; Thomas MC; Thallas V; Dean RG; Burns WC; Tikellis C; Ritchie RH; Twigg SM; Cooper ME; Burrell LM
    Circ Res; 2003 Apr; 92(7):785-92. PubMed ID: 12623881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model.
    Shapiro BP; Lam CS; Patel JB; Mohammed SF; Kruger M; Meyer DM; Linke WA; Redfield MM
    Hypertension; 2007 Sep; 50(3):503-11. PubMed ID: 17620524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes.
    Forbes JM; Thallas V; Thomas MC; Founds HW; Burns WC; Jerums G; Cooper ME
    FASEB J; 2003 Sep; 17(12):1762-4. PubMed ID: 12958202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker.
    Kass DA; Shapiro EP; Kawaguchi M; Capriotti AR; Scuteri A; deGroof RC; Lakatta EG
    Circulation; 2001 Sep; 104(13):1464-70. PubMed ID: 11571237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process.
    Bakris GL; Bank AJ; Kass DA; Neutel JM; Preston RA; Oparil S
    Am J Hypertens; 2004 Dec; 17(12 Pt 2):23S-30S. PubMed ID: 15607432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beneficial effects of C36, a novel breaker of advanced glycation endproducts cross-links, on the cardiovascular system of diabetic rats.
    Cheng G; Wang LL; Long L; Liu HY; Cui H; Qu WS; Li S
    Br J Pharmacol; 2007 Dec; 152(8):1196-206. PubMed ID: 17965740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes.
    Wang Z; Jiang Y; Liu N; Ren L; Zhu Y; An Y; Chen D
    Atherosclerosis; 2012 Apr; 221(2):387-96. PubMed ID: 22305260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
    Forbes JM; Yee LT; Thallas V; Lassila M; Candido R; Jandeleit-Dahm KA; Thomas MC; Burns WC; Deemer EK; Thorpe SR; Cooper ME; Allen TJ
    Diabetes; 2004 Jul; 53(7):1813-23. PubMed ID: 15220206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.